• Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 572.27%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.19
▲ +0.07 (6.25%)

This chart shows the closing price for BIVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIVI

Analyst Price Target is $8.00
▲ +572.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $8.00, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 572.27% upside from the last price of $1.19.

This chart shows the closing price for BIVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in BioVie. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
11/30/2023OppenheimerLower TargetOutperform ➝ Outperform$12.00 ➝ $5.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00Low
7/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$11.00Low
2/14/2023OppenheimerReiterated RatingOutperform$12.00Low
12/12/2022OppenheimerBoost Target$12.00Low
9/28/2022EF Hutton Acquisition Co. ILower TargetBuy$14.00 ➝ $8.00Low
7/22/2022Cantor FitzgeraldInitiated CoverageOverweight$7.00Low
3/14/2022OppenheimerInitiated CoverageOutperform$9.00Low
1/24/2022B. RileyLower Target$27.00 ➝ $18.00High
11/30/2021B. RileyLower TargetBuy$50.00 ➝ $27.00High
7/23/2021B. RileyReiterated RatingBuy$50.00High
5/25/2021B. RileyBoost TargetBuy$47.00 ➝ $50.00High
1/15/2021B. RileyInitiated CoverageBuy$47.00High
(Data available from 2/22/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/26/2023
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
12/24/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/23/2024
  • 6 very positive mentions
  • 35 positive mentions
  • 13 negative mentions
  • 3 very negative mentions
2/22/2024

Current Sentiment

  • 6 very positive mentions
  • 35 positive mentions
  • 13 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

BioVie logo
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Read More

Today's Range

Now: $1.19
Low: $1.09
High: $1.22

50 Day Range

MA: $1.20
Low: $0.91
High: $1.48

52 Week Range

Now: $1.19
Low: $0.89
High: $11.39

Volume

111,853 shs

Average Volume

256,947 shs

Market Capitalization

$47.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of BioVie?

The following Wall Street analysts have issued research reports on BioVie in the last year: Cantor Fitzgerald, and Oppenheimer Holdings Inc..
View the latest analyst ratings for BIVI.

What is the current price target for BioVie?

2 Wall Street analysts have set twelve-month price targets for BioVie in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 572.3%. Cantor Fitzgerald has the highest price target set, predicting BIVI will reach $11.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $5.00 for BioVie in the next year.
View the latest price targets for BIVI.

What is the current consensus analyst rating for BioVie?

BioVie currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BIVI.

What other companies compete with BioVie?

How do I contact BioVie's investor relations team?

The company's listed phone number is (775) 888-3162 and its investor relations email address is [email protected]. The official website for BioVie is bioviepharma.com. Learn More about contacing BioVie investor relations.